Covidien Acquisitions Keeps Buying Spree Alive

Since its spin-out from Tyco, Covidien has spent close to $5 billion acquiring public and privately held device companies, with more than $1 billion of that being spent just over the past six months. The string of purchases bulked up every one of Covidien’s existing medical device businesses. In the recent acquisition of superDimension, Covidien paid $300 million plus earn-outs for the maker of the iLogic system, which uses electromagnetic navigation bronchoscopy technology. The purchase means Covidien’s sales force will begin calling more on interventional pulmonologists, potentially creating an exit route for other pulmonary start-ups.

The only predictable part of Medtronic Minimally Invasive Therapies’s acquisition strategy is there’s no sign of it slowing down. For the past five years, since its spin-out from Tyco International Ltd., [See Deal] the multinational device company has spent close to $5 billion acquiring public and privately held device companies, with more than $1 billion of that being spent just over the past six months on privately held Barrx Medical Inc., Newport Medical Instruments Inc., Reverse Medical Corp., Oridion Systems Ltd., and superDimension Ltd.[See Deal][See Deal][See Deal][See Deal][See Deal]

The string of purchases bulked up every one of Covidien’s existing medical device businesses. (See Exhibit 1.) For example, Covidien’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.